KAT5 Inhibitor NU9056 Suppresses Anaplastic Thyroid Carcinoma Progression through c-Myc/miR-202 Pathway

Figure 7

NU9056 inhibits miR-202-5p expression via transcription factor c-Myc. The possible transcription factors and the potential binding sites of miR-202-5p were predicted by JASPAR (A). 293T cells were transfected with pcDNA3.1 or pcDNA3.1-c-Myc together with PGL4+RL-TK or PGL4-miR-202-5p-promoter, and then, luciferase activity was measured (B). The c-Myc levels in different types of thyroid carcinoma in the Oncomine database (0: no value; 1: follicular variant thyroid gland papillary carcinoma; 2: tall cell variant thyroid gland papillary carcinoma; 3: thyroid gland follicular adenoma; 4: thyroid gland follicular carcinoma; 5: thyroid gland medullary carcinoma; 6: thyroid gland oncocytic adenoma; 7: thyroid gland oncocytic follicular carcinoma; 8: thyroid gland papillary carcinoma; and 9: anaplastic thyroid carcinoma) were analyzed (C). 8505C (D, E) and CAL-62 (D, F) cells were left untreated or treated with NU9056 (2.5–40uM), and then, the expression of c-Myc was detected by Western blot (D) or immunofluorescence (E, F). 8505C (G) and CAL-62 (H) cells were left untreated or treated with NU9056 (2.5–40uM), then, cells were treated with CHX (100 µg/mL) for indicated times, and c-Myc protein levels were analyzed by Western blotting. The half-life values were determined by densitometric quantitation using Image J (G, H).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)